Telomir Pharmaceuticals Inc TELO Q4 2025 Earnings Significant EPS Miss Amid PreClinical Stage Operations ESLT Q1 2026 Earnings EPS Beat Sends Stock Lower Amid Revenue Uncertainty LUMN Q1 2026 Earnings Significant EPS Miss as Company Faces Ongoing Challenges RNG Q1 2026 Earnings EPS Beats Estimates Narrowly as Stock Pulls Back CIFR Q1 2026 Earnings EPS Misses Estimates Amid Operational Challenges Stock Rises 209 BTBT Q1 2026 Earnings Massive EPS Miss as Bit Digital Reports DeeperThanExpected Loss